Angel Giovanni Arietta García

Mr. Angel Giovanni Arietta García

orcid
Universidad Autónoma Metropolitana

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Fernando CalzadaFernando Calzada
Fernando Calzada
Elihú BautistaElihú Bautista
Elihú Bautista
SHSergio Hidalgo-Figueroa
Sergio Hidalgo-Figueroa
Normand García-HernándezNormand García-Hernández
Normand García-Hernández
EBELIZABETH BARBOSA
ELIZABETH BARBOSA
Angel Giovanni Arietta GarcíaAngel Giovanni Arietta García
Angel Giovanni Arietta García
Incomptine A (IA) is a sesquiterpene lactone isolated from Decachaeta incompta that induces apoptosis, reactive oxygen species production, and a differential protein expression on the U-937 (diffuse histiocytic lymphoma) cell line. In this work, the antitumor potential of IA was investigated on Balb/c mice inoculated with U-937 cells and through the brine shrimp lethality (BSL) test. Furthermore, IA was subjected to molecular docking study using as targets proteins associated with processes of cancer as apoptosis, oxidative stress, and glycolytic metabolism. In addition to determining the potential toxicity of IA in human, its acute toxicity was performed in mice. Results reveals that IA showed high antilymphoma activity and BSL with an EC50 of 2.4 mg/kg and LC50 16.7 µg/mL, respectively. The molecular docking study revealed that IA has strong interaction on all targets used. In the acute oral toxicity, IA had a LD50 of 149 mg/kg. The results showed that the activities of IA including antilymphoma activity, BSL, acute toxicity, and in silico interactions were close to the methotrexate, an anticancer drug used as positive control. These findings suggest that IA may serve as a candidate for the development of a new drug to combat lymphoma.

Verified
Journal Article
Open access
PDF file
Angel Giovanni Arietta GarcíaAngel Giovanni Arietta García
Angel Giovanni Arietta García
Fernando CalzadaFernando Calzada
Fernando Calzada
IRIsrael Ramirez-Sanchez
Israel Ramirez-Sanchez
Elihú BautistaElihú Bautista
Elihú Bautista
Normand García-HernándezNormand García-Hernández
Normand García-Hernández
Rosa María Ordoñez-RazoRosa María Ordoñez-Razo
Rosa María Ordoñez-Razo
Breast cancer treatments are limited by the cancer subtype and its selectivity towards tumor cells, hence the importance of finding compounds that increase the survival of healthy cells and target any subtype. Incomptine A (IA) is a sesquiterpene lactone with demonstrated cytotoxic activity. In this study, through in vitro assays, it was observed that IA has similar cytotoxic activity between the subtypes triple negative, HER2+, and luminal A of the breast cancer cell lines. IA cytotoxic activity is higher in cancer than in nontumorigenic cells, and its selectivity index for cancer cells is more than that of the drug doxorubicin. Molecular docking and its in silico comparison with the 2-Deoxyglucose inhibitor suggest that IA could bind to Hexokinase II (HKII), decreasing its expression. Since we did not find changes in the expression of the glycolytic pathway, we suppose that IA could affect the antiapoptotic function of HKII in cancer cells. The IA-HKII union would activate the voltage-gated anion channel 1 (VDAC1), resuming apoptosis. Therefore, we suggest that IA could be used against almost any subtype and that its cytotoxic effect could be due to the reactivation of apoptosis in breast cancer cells.

2 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
Angel Giovanni Arietta GarcíaAngel Giovanni Arietta García
Angel Giovanni Arietta García
Fernando CalzadaFernando Calzada
Fernando Calzada
AFAntonio Franco-Vadillo
Antonio Franco-Vadillo
IBIrais Barrientos-Buendía
Irais Barrientos-Buendía
FAFrancisco Alarcon Aguilar
Francisco Alarcon Aguilar
Rosa María Ordoñez-RazoRosa María Ordoñez-Razo
Rosa María Ordoñez-Razo
Breast cancer (BC) is the most common type of cancer in women worldwide. Hexokinase II (HKII) overexpression is associated with the proliferation and survival of tumor cells, as it inhibits apoptosis. Incomptine A (IA) is cytotoxic to breast cancer cells, likely due to a decrease in the expression of HKII. This study evaluated the antitumor activity of IA in an in vivo mouse model of BC. A model was generated from 4T1 cells and grouped tumor-bearing animals according to treatment: in IA or doxorubicin (DOXO), or untreated (UT). Comparing the body weight and tumor size between groups, tumors were analyzed using histopathological, Western blot, flow cytometry, and mitochondrial activity assays. Tumors IA-treated showed a reduction in size, weight, and number of tumor cells; the expression of HKII and Bcl-2 decreased, while that of Caspase-3 increased. IA treatment increased apoptosis and reduced mitochondrial activity in tumor cells. This data showed that IA has an impact on tumor cells by reducing tumor volume and size, increasing cell apoptosis, and decreasing mitochondrial activity, all of which could be attributed to reduced HKII expression. Therefore, IA may be a promising compound that requires further studies to elucidate its mechanism of action and analyze its possible future use in BC.